Key Highlights
- Launch of Cypris Therapeutics with cutting-edge synthetic chemistry technology.
- Focus on developing treatments for resistant diseases including brain and pancreatic cancers.
- Proprietary technology enhances therapeutic properties of natural molecules.
- Backed by Ichor Life Sciences with over $500,000 in pre-seed funding.
- Committed to delivering innovative cancer treatments.
Source: Business Wire
Notable Quotes
- “We see vast potential in Cypris Therapeutics’ technology not only as a promising opportunity to develop next generation oncology treatments, but as a platform for iterating natural products for other age-related indications where traditional medicinal chemistry approaches have been elusive.” — Kelsey Moody, PhD, MBA, CEO and Founder at Ichor Life Sciences
- “At Cypris Therapeutics, we are driven by a mission to develop life-saving therapies for some of the deadliest and therapeutically challenging diseases. Our technology represents a new frontier in cancer treatment, offering hope to patients who currently have limited options.” — Kyle Parella, PhD, Co-Founder and CEO at Cypris Therapeutics
SoHC's Take
The launch of Cypris Therapeutics marks a significant milestone in the field of drug discovery, especially for diseases that have resisted conventional treatments. The company’s innovative approach in utilizing synthetic chemistry to enhance natural molecules is poised to revolutionize cancer therapy. Backed by Ichor Life Sciences, Cypris not only has the financial support but also the strategic resources necessary for rapid development and commercialization of its groundbreaking treatments. This launch is a promising step forward for patients battling some of the most challenging and life-threatening diseases.
